#VisionforEurope: Innovation, Investment, Excellence

28/02/2023

How do we live in a bioeconomy? EuropaBio at the Swedish EU Council Presidency conference

23/02/2023

EuropaBio Response to Public Consultation on Horizon Europe – interim evaluation

17/02/2023

Inter-association letter to raise our concern about the proposed definition of “natural polymers” in the REACH restriction of microplastics

13/12/2022

EuropaBio Principles for Genetic Testing and Testing for Genetically-Driven Risk Factor

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.

08/12/2022

‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.

02/12/2022

EuropaBio’s 2022 Patient BioForum addresses the challenges of patients with unmet medical needs and calls for multi-stakeholder approach

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.

28/11/2022

Enabling Patient Access to Transformational Therapeutic Innovations: Modernising the EU’s Cross-Border Healthcare Framework

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.

23/11/2022

Innovation, Investment, and Excellence for Healthcare Biotechnology: Achieving a competitive environment in Europe | EuropaBio Healthcare BioForum, October 2022

EuropaBio hosted its inaugural Healthcare BioForum on October 5, 2022. The roundtable brought together representatives from SMEs, large companies, DGs GROW, Santé and RTD, European Parliament and Member States to discuss links between innovation, investment, and excellence in European healthcare biotechnology.

11/11/2022

The Revision of the Orphan Medicines Regulation Is an Opportunity. Will Europe Seize it?

20/10/2022

Ensuring the full potential of EHDS: Stakeholders’ recommendations on how to make the digital transformation a success across Europe

11/10/2022

How do we live in a bioeconomy? EuropaBio at the Swedish EU Council Presidency conference

EuropaBio Response to Public Consultation on Horizon Europe – interim evaluation

Inter-association letter to raise our concern about the proposed definition of “natural polymers” in the REACH restriction of microplastics

EuropaBio Principles for Genetic Testing and Testing for Genetically-Driven Risk Factor

‘Rare Disease Moonshot’ – Scaling-up public-private partnerships to accelerate research into world’s rarest diseases

EuropaBio’s 2022 Patient BioForum addresses the challenges of patients with unmet medical needs and calls for multi-stakeholder approach

Enabling Patient Access to Transformational Therapeutic Innovations: Modernising the EU’s Cross-Border Healthcare Framework

Innovation, Investment, and Excellence for Healthcare Biotechnology: Achieving a competitive environment in Europe | EuropaBio Healthcare BioForum, October 2022

The Revision of the Orphan Medicines Regulation Is an Opportunity. Will Europe Seize it?

Ensuring the full potential of EHDS: Stakeholders’ recommendations on how to make the digital transformation a success across Europe

Factsheet – Vision for Europe: Excellence

Factsheet – Vision for Europe: Investment

Factsheet – Vision for Europe: Innovation

EuropaBio celebrates its inaugural Healthcare BioForum

Vision for Europe: Innovation, Investment, Excellence | Claire Skentelbery, EuropaBio

Collaboration, expertise, and infrastructure: key ingredients for gene therapy to thrive in Europe

Vision for Europe:Innovation, Investment, Excellence | Yordan Aleksandrov, Pfizer

Vision for Europe: Innovation, Investment, Excellence | Tineke Van hooland, bio.be/essenscia

Vision for Europe: Innovation, Investment, Excellence | Thomas Bols, PTC Therapeutics